Cramer lauds Eli Lilly’s GLP-1 dominance and strategic pivots as AI headwinds loom
Jim Cramer describes CEO David Ricks as a top-tier steward of capital, recommending a long-term hold on Eli Lilly shares despite broader market concerns over technology sector spending.
Financial commentator Jim Cramer has issued a strong endorsement of Eli Lilly and Company, praising CEO David Ricks as a “terrific steward of his shareholders’ capital.” The assessment comes as Cramer outlines a series of recent bullish developments for the pharmaceutical giant, positioning the stock as a stable long-term holding amidst broader market volatility.
Cramer identified Eli Lilly’s superior GLP-1 franchise as the core thesis for his recommendation, noting that the company currently holds the most effective weight-loss drugs in the pipeline. He pointed specifically to Phase 3 trial data released on 21 May for Retatrutide, which showed significantly greater efficacy for weight loss compared to existing GLP-1 treatments.
Beyond pure efficacy, Cramer highlighted speculation that Retatrutide may better preserve muscle mass than current options, addressing a common side effect of the drug class. This potential advantage has driven substantial demand in the “gray market,” with Cramer suggesting the drug could become one of the most significant pharmaceutical products in history due to its unique position in the market.
The commentator also noted a shift in the company’s strategic breadth, citing two major developments from late May. On 25 May, Eli Lilly announced promising early-stage Phase 1 results for a gene therapy targeting high cholesterol, which could pave the way for a one-time treatment. This was followed on 26 May by the acquisition of three vaccine manufacturers, marking the company’s first major push into a sector where it previously lacked a significant presence.
Further bolstering the company’s commercial outlook, Cramer highlighted a distribution agreement secured on 28 May with CVS Caremark to cover the weight-loss drugs Zepbound and Mounjaro. He contrasted Eli Lilly’s fundamental strength with the technology sector, warning that high spending on artificial intelligence could create near-term headwinds for tech stocks, whereas Eli Lilly offers greater stability and upside potential for investors.
